Study Summary:
We are currently conducting a study to investigate the pharmacokinetics of CP-70429 after IV CP-70429 and oral PF-03709270 administration, in both healthy subjects and subjects with mild, moderate and severe renal impairment.
Qualified Participants Must:
• Be 18-85 years of age
•
Have a BMI between 18 and 30
•
Have severe kidney impairment
Qualified Participants May Receive:
Compensation up to $2,000